Aloxi

Patients scheduled to undergo chemotherapy may wish to speak with their physician about the risks and benefits of receiving anti-emetics such as Aloxi® to prevent or reduce CINV.

unknown title 2009

The researchers in this study stated that use of newer acting agents, such as Aloxi®, which is the only approved agent for delayed CINV and the preferred agent for chemotherapy that is moderately or highly associated with nausea and vomiting according to the 2004 NCCN guidelines, may help to alleviate delayed CINV, particularly if used routinely in the prevention of CINV.

unknown title 2009

The researchers in this study stated that use of newer acting agents, such as Aloxi®, which is the only approved agent for delayed CINV and the preferred agent for chemotherapy that is moderately or highly associated with nausea and vomiting according to the 2004 NCCN guidelines, may help to alleviate delayed CINV, particularly if used routinely in the prevention of CINV.

unknown title 2009

Patients scheduled to undergo chemotherapy may wish to speak with their physician about the risks and benefits of receiving anti-emetics such as Aloxi® to prevent or reduce CINV.

unknown title 2009

Aloxi is a drug is used to prevent nausea and vomiting that may occur within 24 hours after receiving chemotherapy.

Hollye Harrington Jacobs: Breast Cancer Chemotherapy 1st Cycle, Round 2 Hollye Harrington Jacobs 2011

Aloxi is a drug is used to prevent nausea and vomiting that may occur within 24 hours after receiving chemotherapy.

Hollye Harrington Jacobs: Breast Cancer Chemotherapy 1st Cycle, Round 2 Hollye Harrington Jacobs 2011

Then, in June, after MGI stock had rebounded to around $23 -- in part because of the successful completion of trials on its Aloxi cancer treatment -- Mr. Naito raised the offer to $33, a 53% premium to MGI's share price then.

Buffett Banker's Christmas Gift 2007

The company said the expected shortfall was attributed to an earlier than expected generic launch of GlaxoSmithKline's Zofran, a cancer-related painkiller similar to MGI's Aloxi.

Big Pharma Bounces On Strong Q2 Earnings 2006

"We continue to believe that with a full pipeline and a strong base of sales supported by Aloxi, MGI Pharma represents a solid company with great growth and good value at these levels," the research analyst said.

MGI Pharma Still A 'Solid Company' Despite Mixed Guidance 2006

Banc of America Securities analyst David Maris lowered the price target on MGI Pharma to $24 from $30 after the company pre-announced slightly lower-than-expected fourth-quarter sales of Aloxi, its post-chemotherapy nausea treatment, and Gliadel, a brain tumor treatment.

MGI Pharma Still A 'Solid Company' Despite Mixed Guidance 2006